WINTON GROUP Ltd Acquires Shares of 15,085 Meridian Bioscience, Inc. (NASDAQ:VIVO)

WINTON GROUP Ltd acquired a new stake in Meridian Bioscience, Inc. (NASDAQ:VIVOGet Rating) during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 15,085 shares of the company’s stock, valued at approximately $459,000.

A number of other large investors also recently modified their holdings of the company. Envestnet Asset Management Inc. increased its position in shares of Meridian Bioscience by 0.8% in the 2nd quarter. Envestnet Asset Management Inc. now owns 41,308 shares of the company’s stock valued at $1,257,000 after purchasing an additional 341 shares during the last quarter. Financial Gravity Asset Management Inc. acquired a new position in shares of Meridian Bioscience in the 2nd quarter valued at $2,668,000. Texas Permanent School Fund boosted its holdings in shares of Meridian Bioscience by 2.0% in the 2nd quarter. Texas Permanent School Fund now owns 31,495 shares of the company’s stock valued at $958,000 after buying an additional 626 shares in the last quarter. Arizona State Retirement System boosted its holdings in shares of Meridian Bioscience by 6.0% in the 2nd quarter. Arizona State Retirement System now owns 11,800 shares of the company’s stock valued at $359,000 after buying an additional 664 shares in the last quarter. Finally, Advisor Group Holdings Inc. boosted its holdings in shares of Meridian Bioscience by 6.1% in the 1st quarter. Advisor Group Holdings Inc. now owns 16,453 shares of the company’s stock valued at $464,000 after buying an additional 940 shares in the last quarter. 93.65% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, StockNews.com cut shares of Meridian Bioscience from a “buy” rating to a “hold” rating in a report on Saturday.

Meridian Bioscience Stock Up 0.3 %

Shares of NASDAQ:VIVO opened at $32.03 on Friday. The stock has a market cap of $1.40 billion, a P/E ratio of 32.35 and a beta of 0.28. The firm has a fifty day moving average price of $32.02 and a 200 day moving average price of $30.77. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.52 and a quick ratio of 2.36. Meridian Bioscience, Inc. has a 1-year low of $17.20 and a 1-year high of $34.38.

About Meridian Bioscience

(Get Rating)

Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H.

Read More

Want to see what other hedge funds are holding VIVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Meridian Bioscience, Inc. (NASDAQ:VIVOGet Rating).

Institutional Ownership by Quarter for Meridian Bioscience (NASDAQ:VIVO)

Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.